Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

3,399 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Reactivation of ERK signaling causes resistance to EGFR kinase inhibitors.
Ercan D, Xu C, Yanagita M, Monast CS, Pratilas CA, Montero J, Butaney M, Shimamura T, Sholl L, Ivanova EV, Tadi M, Rogers A, Repellin C, Capelletti M, Maertens O, Goetz EM, Letai A, Garraway LA, Lazzara MJ, Rosen N, Gray NS, Wong KK, Jänne PA. Ercan D, et al. Among authors: rogers a. Cancer Discov. 2012 Oct;2(10):934-47. doi: 10.1158/2159-8290.CD-12-0103. Epub 2012 Sep 7. Cancer Discov. 2012. PMID: 22961667 Free PMC article.
Amplification of EGFR T790M causes resistance to an irreversible EGFR inhibitor.
Ercan D, Zejnullahu K, Yonesaka K, Xiao Y, Capelletti M, Rogers A, Lifshits E, Brown A, Lee C, Christensen JG, Kwiatkowski DJ, Engelman JA, Jänne PA. Ercan D, et al. Among authors: rogers a. Oncogene. 2010 Apr 22;29(16):2346-56. doi: 10.1038/onc.2009.526. Epub 2010 Feb 1. Oncogene. 2010. PMID: 20118985 Free PMC article.
Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC.
Turke AB, Zejnullahu K, Wu YL, Song Y, Dias-Santagata D, Lifshits E, Toschi L, Rogers A, Mok T, Sequist L, Lindeman NI, Murphy C, Akhavanfard S, Yeap BY, Xiao Y, Capelletti M, Iafrate AJ, Lee C, Christensen JG, Engelman JA, Jänne PA. Turke AB, et al. Among authors: rogers a. Cancer Cell. 2010 Jan 19;17(1):77-88. doi: 10.1016/j.ccr.2009.11.022. Cancer Cell. 2010. PMID: 20129249 Free PMC article.
Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab.
Yonesaka K, Zejnullahu K, Okamoto I, Satoh T, Cappuzzo F, Souglakos J, Ercan D, Rogers A, Roncalli M, Takeda M, Fujisaka Y, Philips J, Shimizu T, Maenishi O, Cho Y, Sun J, Destro A, Taira K, Takeda K, Okabe T, Swanson J, Itoh H, Takada M, Lifshits E, Okuno K, Engelman JA, Shivdasani RA, Nishio K, Fukuoka M, Varella-Garcia M, Nakagawa K, Jänne PA. Yonesaka K, et al. Among authors: rogers a. Sci Transl Med. 2011 Sep 7;3(99):99ra86. doi: 10.1126/scitranslmed.3002442. Sci Transl Med. 2011. PMID: 21900593 Free PMC article.
Mutations in the LKB1 tumour suppressor are frequently detected in tumours from Caucasian but not Asian lung cancer patients.
Koivunen JP, Kim J, Lee J, Rogers AM, Park JO, Zhao X, Naoki K, Okamoto I, Nakagawa K, Yeap BY, Meyerson M, Wong KK, Richards WG, Sugarbaker DJ, Johnson BE, Jänne PA. Koivunen JP, et al. Among authors: rogers am. Br J Cancer. 2008 Jul 22;99(2):245-52. doi: 10.1038/sj.bjc.6604469. Epub 2008 Jul 1. Br J Cancer. 2008. PMID: 18594528 Free PMC article.
MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling.
Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, Park JO, Lindeman N, Gale CM, Zhao X, Christensen J, Kosaka T, Holmes AJ, Rogers AM, Cappuzzo F, Mok T, Lee C, Johnson BE, Cantley LC, Jänne PA. Engelman JA, et al. Among authors: rogers am. Science. 2007 May 18;316(5827):1039-43. doi: 10.1126/science.1141478. Epub 2007 Apr 26. Science. 2007. PMID: 17463250
3,399 results